Zealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021
Zealand Pharma will host a conference call on March 10, 2022, at 4 PM CET (10 AM ET) to discuss its full-year results for 2021. Key executives, including President and CEO Emmanuel Dulac, will present and engage in a Q&A session. Interested participants can connect via dial-in numbers provided for various regions, including the U.S. and Europe. A live audio webcast of the call will be available on Zealand's investor website, along with a recording and transcript post-event. Zealand Pharma focuses on innovative peptide-based medicines.
- None.
- None.
Company announcement – No. 6 / 2022
Zealand Pharma Hosts Conference Call on March 10 at 4 pm CET (10am ET) to Present Full Year Results for 2021
Copenhagen, DK and Boston, MA, U.S. March 3, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that it will host a conference call on March 10, 2022 at 4 pm CET (10 am ET) following the announcement of results for the full year of 2021.
Presenting during the call will be President and Chief Executive Officer Emmanuel Dulac, President of Zealand Pharma U.S. Frank Sanders, Senior Vice President and Chief Financial Officer Matt Dallas, and Executive Vice President and Chief Medical Officer Adam Steensberg. The presentation will be followed by a Q&A session. The conference call will be conducted in English, and the dial-in numbers are:
| Denmark, Copenhagen........... | +45 32 720 417 |
| Denmark, tollfree........................ | +80 711 246 |
| France, Paris................................ | +33 (0) 170 700 781 |
| Netherlands, Amsterdam........ | +31 (0) 207956614 |
| United Kingdom......................... | +44 (0) 844 481 9752 |
| United States................................. | +1 646 741 3167 |
| International................................ | +44 (0) 2071 928338 |
| Confirmation Code: ................ | 9554999 |
A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/mmc/p/34a8yoe2, and will be accessible on the Investor section of Zealand’s website (www.zealandpharma.com/investor). Due to increased demand of conference call services, it could take longer to be connected to the call. Participants are advised to register for the webcast 30 minutes before the scheduled start, if possible. A recording of the event and a transcript will be available on the Investor section of Zealand’s website after the call.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statements
This announcement may contain forward-looking statements, including “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on the beliefs and assumptions and on information currently available to management of Zealand, including with respect to the company’s anticipated revenue and expenses for 2021 and potential product approval by the FDA. All statements other than statements of historical fact contained in this announcement are forward-looking statements, including statements regarding the anticipated final terms of the Investment. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Zealand's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Zealand's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and subsequent reports that Zealand has filed or will file with the SEC. Forward-looking statements represent Zealand's beliefs and assumptions only as of the date of this announcement. Although Zealand believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, Zealand assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this announcement to conform any of the forward-looking statements to actual results or to changes in its expectations.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Maeve Conneighton |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What date is Zealand Pharma's conference call for 2021 results?
What time will the conference call occur for Zealand Pharma?
Who will present during Zealand Pharma's conference call?
How can I access the conference call for Zealand Pharma?
What is the focus of Zealand Pharma's business?
